Hepatitis Test Solution Market - Emerging Trends Expected to Boost the Revenue at a Healthy Rate by 2023

The global hepatitis test solution market is expected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, at a CAGR of 4.9% during the forecast period (2018–2023).

(EMAILWIRE.COM, June 24, 2021 ) Major Growth Boosting Factors:

Hepatitis Test Diagnosis Market is primarily driven by factors such as the high burden of hepatitis worldwide, increasing number of blood transfusions and donations, benefits offered by PoC instruments & kits, and awareness initiatives. Emerging markets such as China, India, Brazil, and Africa are expected to offer lucrative growth opportunities for the players in this market. However, the high cost of NAT tests and a lack of mandate for NAT in developing countries are expected to restrain the growth of this market during the forecast period.

The ELISA segment is expected to account for the largest share of the global hepatitis test solution/diagnosis market, by technology. The large share of ELISA is mainly driven by the wide acceptance of this test in clinical practices to diagnose hepatitis. Rapid diagnostics test segment is expected to register the highest CAGR during the forecast period. High growth of rapid diagnostics test segment can be attributed to the low cost of this test type, its high analytical sensitivity, and its ability to detect all known 11 subtypes of HBsAg.

The hospital and diagnostics laboratories segment is expected to account for the largest share of hepatitis test solution/diagnosis market, by end user, in 2018 and is expected to register the highest CAGR during the forecast period. This can primarily be attributed to the growing patient population, increase in Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=139802887

Geographically, the hepatitis test solution market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2018 North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market. The large share of the North America region is mainly attributed to factors such as the developed healthcare systems in the US and Canada, rising adoption of advanced technologies, and the presence of a large number of leading national clinical laboratories.

The APAC region is projected to grow at the highest CAGR during the forecast period. The growth of the Hepatitis Test Diagnosis Market in this region is driven by the widespread prevalence of hepatitis infections, increased healthcare spending by a larger population base, and modernization of healthcare infrastructure.

Nucleic Acid Tests (NATs) are relatively more expensive hepatitis diagnostic techniques than ELISA tests as the cost of NAT instruments is higher, in terms of outright purchases as well as rental agreements. NAT instruments require heavy investments, which most blood banks cannot afford. As a result, most end users opt for ELISA (serology) testing for hepatitis diagnosis, which limits the growth of the hepatitis testing market to a certain extent.

Global Key Players:

The key players in the Hepatitis Test Diagnosis Market are Roche (Switzerland), Abbott Laboratories (US), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), Danaher (US), bioMérieux (France), and Grifols (Spain).

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=139802887

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com